Dashboard
Manage Tickers

CORT CORCEPT THERAPEUTICS INC

Nasdaq corcept.com


$ 78.69 $ -0.78 (-0.98 %)    

Friday, 17-Oct-2025 19:45:53 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 78.69
$ 78.63
$ 73.00 x 17
$ 84.98 x 2,000
$ 76.44 - $ 80.24
$ 42.01 - $ 117.33
1,331,235
na
8.29B
$ 0.46
$ 62.82
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-31-2025 06-30-2025 10-Q
2 05-05-2025 03-31-2025 10-Q
3 02-26-2025 12-31-2024 10-K
4 10-30-2024 09-30-2024 10-Q
5 07-29-2024 06-30-2024 10-Q
6 05-01-2024 03-31-2024 10-Q
7 02-15-2024 12-31-2023 10-K
8 11-01-2023 09-30-2023 10-Q
9 08-02-2023 06-30-2023 10-Q
10 05-03-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 05-05-2022 03-31-2022 10-Q
15 02-15-2022 12-31-2021 10-K
16 11-03-2021 09-30-2021 10-Q
17 07-29-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-23-2021 12-31-2020 10-K
20 11-03-2020 09-30-2020 10-Q
21 08-04-2020 06-30-2020 10-Q
22 05-04-2020 03-31-2020 10-Q
23 02-24-2020 12-31-2019 10-K
24 11-07-2019 09-30-2019 10-Q
25 08-01-2019 06-30-2019 10-Q
26 05-09-2019 03-31-2019 10-Q
27 02-26-2019 12-31-2018 10-K
28 11-02-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-09-2018 03-31-2018 10-Q
31 02-28-2018 12-31-2017 10-K
32 11-03-2017 09-30-2017 10-Q
33 08-02-2017 06-30-2017 10-Q
34 05-02-2017 03-31-2017 10-Q
35 03-06-2017 12-31-2016 10-K
36 11-02-2016 09-30-2016 10-Q
37 08-03-2016 06-30-2016 10-Q
38 05-04-2016 03-31-2016 10-Q
39 03-10-2016 12-31-2015 10-K
40 11-06-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

corcept-submits-marketing-authorization-application-to-european-medicines-agency-for-relacorilant-for-patients-with-platinum-resistant-ovarian-cancer
Corcept Submits Marketing Authorization Ap...
10/14/2025 12:08:07

in-an-sec-filing-on-tuesday-corcept-therapeutics-said-on-friday-the-company-announced-the-termination-of-the-distribution-agreement-with-optime-care-8k
In An SEC Filing On Tuesday, Corcept Thera...
10/14/2025 10:47:15

As previously disclosed, under the terms of the Agreement, Optime has acted as a specialty pharmacy distributor of Korlym and t...

hc-wainwright--co-reiterates-buy-on-corcept-therapeutics-maintains-145-price-target
HC Wainwright & Co. Reiterates Buy on Corc...
10/10/2025 11:06:23

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Corcept Therapeutics (NASDAQ:CORT) with a Buy and maintain...

4-biotechnology-stocks-that-outshine-in-momentum-amid-strong-technicals
4 Biotechnology Stocks That Outshine In Mo...
09/29/2025 11:11:04

Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week ...

what-analysts-are-saying-about-corcept-therapeutics-stock
What Analysts Are Saying About Corcept The...
09/25/2025 13:00:43

Throughout the last three months, 4 analysts have evaluated Corcept Therapeutics (NASDAQ: CORT), offering a diverse set of opin...

canaccord-genuity-maintains-buy-on-corcept-therapeutics-maintains-140-price-target
Canaccord Genuity Maintains Buy on Corcept...
09/25/2025 12:32:43

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ: CORT) with a Buy and maintains $140 price targ...

corcept-therapeutics-to-present-new-data-from-pivotal-phase-3-rosella-trial-of-relacorilant-plus-nab-paclitaxel-in-patients-with-platinum-resistant-ovarian-cancer-at-2025-esmo
Corcept Therapeutics To Present New Data F...
09/22/2025 18:31:28

Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medicat...

canaccord-genuity-maintains-buy-on-corcept-therapeutics-raises-price-target-to-140
Canaccord Genuity Maintains Buy on Corcept...
09/10/2025 14:21:15

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target fr...

fda-accepts-corcepts-nda-for-relacorilant-in-platinum-resistant-ovarian-cancer-sets-pdufa-date-for-july-11-2026
FDA Accepts Corcept's NDA For Relacorilant...
09/10/2025 12:08:03

FDA assigns a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026Corcept Therapeutics Incorporated (NASDAQ:CORT), a co...

canaccord-genuity-maintains-buy-on-corcept-therapeutics-lowers-price-target-to-137
Canaccord Genuity Maintains Buy on Corcept...
08/01/2025 15:14:20

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and lowers the price target fr...

if-you-invested-100-in-this-stock-5-years-ago-you-would-have-this-much-today
If You Invested $100 In This Stock 5 Years...
08/01/2025 15:00:24

piper-sandler-maintains-overweight-on-corcept-therapeutics-lowers-price-target-to-121
Piper Sandler Maintains Overweight on Corc...
08/01/2025 12:08:29

Piper Sandler analyst David Amsellem maintains Corcept Therapeutics (NASDAQ:CORT) with a Overweight and lowers the price tar...

corcept-therapeutics-lowers-fy2025-sales-guidance-from-900000m-950000m-to-850000m-900000m-vs-899047m-est
Corcept Therapeutics Lowers FY2025 Sales G...
07/31/2025 20:07:37

Financial Results"The second quarter marked another period of robust growth in our hypercortisolism business. Once again, w...

corcept-therapeutics-q2-eps-029-beats-019-estimate-sales-194430m-miss-199395m-estimate
Corcept Therapeutics Q2 EPS $0.29 Beats $0...
07/31/2025 20:06:43

Corcept Therapeutics (NASDAQ:CORT) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of ...

Core News & Articles
Earnings Scheduled For July 31, 2025
07/31/2025 08:32:50

heres-how-much-you-would-have-made-owning-corcept-therapeutics-stock-in-the-last-5-years
Here's How Much You Would Have Made Owning...
07/21/2025 14:30:25

whats-driving-the-market-sentiment-around-corcept-therapeutics
What's Driving the Market Sentiment Around...
07/17/2025 16:00:41

corcept-submits-new-drug-application-for-relacorilant-to-fda
Corcept Submits New Drug Application For R...
07/14/2025 12:01:29

heres-how-much-100-invested-in-corcept-therapeutics-20-years-ago-would-be-worth-today
Here's How Much $100 Invested In Corcept T...
07/04/2025 14:15:14

corcept-therapeutics-reveals-that-catalyst-trial-meets-primary-endpoint-with-improvement-in-hba1c-catalyst-trial-meets-secondary-endpoints-with-reduced-body-weight-and-waist-circumference
Corcept Therapeutics Reveals That Catalyst...
06/23/2025 20:34:30

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION